

We claim:

1. A PD1 binder comprising an immunoglobulin single variable domain (ISVD) that binds to PD1 comprising the amino acid sequence set forth in SEQ ID NO: 1 or 2 but comprising one or more mutations at a residue selected from 11 and 89;
 5 wherein said residue numbers are Kabat residue numbers;
 and, optionally, a half-life extender and/or a C-terminal extender.

2. A PD1 binder comprising one or more immunoglobulin single variable domains (ISVDs) that binds to PD1 comprising:
 - 10 a CDR1 comprising the amino acid sequence `IHAMG` (SEQ ID NO: 3) or `GSIASIHAMG` (SEQ ID NO: 6);
 - a CDR2 comprising the amino acid sequence `VITXSGGITYYADSVKG` (SEQ ID NO: 4; wherein X is W or V) or `VITXSGGITY` (SEQ ID NO: 7; wherein X is W or V); and
 - a CDR3 comprising the amino acid sequence `DKHQSSXYDY` (SEQ ID NO: 5, wherein X is W or F);
 - 15 comprising one or more mutations at a residue selected from 11 and 89, wherein said residue numbers are Kabat residue numbers.

3. The PD1 binder of any one of claims 1-2 wherein the immunoglobulin single variable domain comprises the amino acid sequence:
 - 20 `DVQLVESGGG VVQPGGSLRL SCAASGSIAS IHAMGWFRQA PGKEREFAV ITWSGGITYY`
`ADSVKGRFTI SRDNSKNTVY LQMNSLRPED TALYYCAGDK HQSSWYDYWG QGTLVTVSS`
 (SEQ ID NO: 57, optionally comprising a D1E mutation);
 - `EVQLVESGGGLVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFAVITWSGGITYYADSVKGRFTISRDN SKNT`
`VY LQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTVSS`
 25 (SEQ ID NO: 98, optionally comprising a E1D mutation);
 - `EVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFAVITWSGGITYYADSVKGRFTISRDN SKNT`
`VY LQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTVSS`
 (SEQ ID NO: 99, optionally comprising a E1D mutation);
 - `DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFAVITVSGGITYYADSVKGRFTISRDN SKNT`
`VY LQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS`
 30 (SEQ ID NO: 103, optionally comprising a D1E and/or N73S mutation);
 - `DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFAVITVSGGITYYADSVKGRFTISRDN SKNT`
`VY LQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS`
 (SEQ ID NO: 104, optionally comprising a D1E mutation); or

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDP SKNT
 VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGLTVTVSS

(SEQ ID NO: 105, optionally comprising a D1E mutation), or

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDP SKNT

- 5 VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGLTVTVSS (amino acids 1-19 of SEQ ID NO: 113,
 optionally comprising a D1E mutation); or

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDP SKNT

VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGLTVTVSS (amino acids 1-19 of SEQ ID NO: 117,
 optionally comprising a D1E mutation); or

- 10 DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDP SKNT

VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGLTVTVSS (amino acids 1-19 of SEQ ID NO: 121,
 optionally comprising a D1E mutation);

and, optionally, comprising a half-life extender and/or a C-terminal extender.

- 15 4. A LAG3 binder comprising an immunoglobulin single variable domain (ISVD) that binds
 to LAG3 comprising

a CDR1 comprising the amino acid sequence GRTFSDYVMG (SEQ ID NO: 65) or DYVMG (amino
 acids 6-10 of SEQ ID NO: 65);

a CDR2 comprising the amino acid sequence AISESGGRTHYADSVKG (SEQ ID NO: 66) or

- 20 AISESGGRTH (amino acids 1-10 of SEQ ID NO: 66); and

a CDR3 comprising the amino acid sequence TLLWWTSEYAPIKANDYD (SEQ ID NO: 67); and,
 optionally, a half-life extender and/or a C-terminal extender..

5. The LAG3 binder of claim 4 wherein the immunoglobulin single variable domain

- 25 comprises the amino acid sequence:

EVQLVE SGGGVVQPGG SLRLSCAASG RTFSDYVMGW FRQAPGKERE FVA AISESGG RTHYADSVKG

RFTISRDN SK NTLYLQMNSL RPEDTALYYC ATLLWWTSE YAPIKANDYD YWGQGLTVTV SS

(SEQ ID NO: 64); optionally comprising a E1D mutation, and optionally, comprising a half-life
 extender and/or a C-terminal extender.

30

6. A multispecific binder comprising an immunoglobulin single variable domain (ISVD) that
 binds to PD1 comprising:

- a CDR1 comprising the amino acid sequence IHAMG (SEQ ID NO: 3) or GSIASIHAMG (SEQ ID NO: 6);
- a CDR2 comprising the amino acid sequence VITXSGGITYYADSVKG (SEQ ID NO: 4; wherein X is W or V) or VITXSGGITY (SEQ ID NO: 7; wherein X is W or V); and
- 5 a CDR3 comprising the amino acid sequence DKHQSSXYDY (SEQ ID NO: 5, wherein X is W or F); and
- an immunoglobulin single variable domain that binds to LAG3 comprising:
- a CDR1 comprising the amino acid sequence GRTFSDYVMG (SEQ ID NO: 65) or DYVMG (amino acids 6-10 of SEQ ID NO: 65);
- 10 a CDR2 comprising the amino acid sequence AISESGGRTHYADSVKG (SEQ ID NO: 66) or AISESGGRTH (amino acids 1-10 of SEQ ID NO: 66); and
- a CDR3 comprising the amino acid sequence TLLWWTSEYAPIKANDYDY (SEQ ID NO: 67); and, optionally, a half-life extender and/or a C-terminal extender.
- 15 7. The multispecific binder of claim 6 wherein the immunoglobulin single variable domain that binds to PD1 comprises the amino acid sequence:
- DVQLVESGGG VVQPGGSLRL SCAASGSIAS IHAMGWFRQA PGKEREFAV ITWSSGGITYY
ADSVKGRFTI SRDNSKNTVY LQMNSLRPED TALYYCAGDK HQSSWYDYWG QGTLVTVSS
(SEQ ID NO: 57);
- 20 EVQLVESGGGLVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFAVITWSSGGITYYADSVKGRFTISRDNKNT
VYLLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTVSS
(SEQ ID NO: 98);
- EVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFAVITWSSGGITYYADSVKGRFTISRDNKNT
VYLLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTVSS
(SEQ ID NO: 99);
- 25 DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFAVITWSSGGITYYADSVKGRFTISRDNKNT
VYLLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTVSS
(amino acids 1-119 of SEQ ID NO: 101);
- DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFAVITVSSGGITYYADSVKGRFTISRDNKNT
30 VYLLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS
(SEQ ID NO: 103);
- DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFAVITVSSGGITYYADSVKGRFTISRDSKNT
VYLLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS
(SEQ ID NO: 104);

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDP SKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGLTVTVSS

(SEQ ID NO: 105);

the immunoglobulin single variable domain that binds to LAG3 comprises the amino acid

5 sequence:

EVQLVE SGGGVVQPGG SLRLSCAASG RTFSDYVMGW FRQAPGKERE FVAAISESGG RTHYADSVKG
RFTISRDN SK NTLYLQMNSL RPEDTALYYC ATTLLWWTSE YAPIKANDYD YWGQGLTVTV SS

(SEQ ID NO: 64); or

10 DVQLVESGGGVVQPGGSLRLSCAASGRTFSDYVMGWFRQAPGKEREFVAAISESGGRTHYADSVKGRFTISRDN SKNTLYLQMNSLR
PEDTALYYCATTLLWWTSEYAPIKANDYDYWGQGLTVTVSS

(amino acids 1-128 of SEQ ID NO: 96);

and, optionally, a half-life extender and/or a C-terminal extender.

8. The binder of any one of claims 1-7 comprising a C-terminal extender wherein the C-
15 terminal extender is an alanine.

9. The multispecific binder of any one of claims 6-7 comprising:

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 98;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- 20 • a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 98;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 63;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 63;
- 25 • a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine

or

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- 30 • a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 99;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;

- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- 5 • a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine

or

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- a 20 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- 10 • a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 99;
- a 20 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 20 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- 15 • a 20 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine

or

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- 20 • a 9 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 99;
- a 9 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- 25 • a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine

or

- 30 • a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;

- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
 - a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
 - a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
 - a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
 - 5 • a C-terminal Alanine
- or
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
 - a 20GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
 - a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
 - 10 • a 20GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
 - a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
 - a C-terminal Alanine
- or
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
 - 15 • a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
 - a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
 - a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
 - a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
 - a C-terminal Alanine
- 20 or
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105;
 - a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
 - a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105 (D1E);
 - av35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
 - 25 • a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
 - a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
 - a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
 - a C-terminal Alanine
- or
- 30 • a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105;

- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
 - a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105 (D1E);
 - a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
 - a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
 - 5 • a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
 - a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
 - a C-terminal Alanine
- or
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105;
 - 10 • a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
 - a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
 - a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
 - a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
 - a C-terminal Alanine
- 15 or
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105;
 - a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
 - a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
 - a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
 - 20 • a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
 - a C-terminal Alanine
- or
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104;
 - a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
 - 25 • a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104 (D1E);
 - a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
 - a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
 - a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
 - a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
 - 30 • a C-terminal Alanine

or

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104 (D1E);
- 5 • a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine

10 or

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- 15 • a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine

or

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- 20 • a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine

or

- 25 • a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (N73S);
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (D1E, N73S);
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- 30 • a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;

- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine

or

- 5 • a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (N73S);
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (D1E, N73S);
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- 10 • a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine

or

- 15 • a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (N73S);
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- 20 • a C-terminal Alanine

or

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (N73S);
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- 25 • a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine.

10. The multispecific binder of any one of claims 6-9 comprising the amino acid sequence
30 selected from SEQ ID NOs: 106-124.

11. The multispecific binder of any one of claims 1-10 which is bound to PD1 and/or LAG3.
12. The multispecific binder of any one of claims 1-8 comprising a half-life extender wherein
 5 the half-life extender is a human serum albumin ISVD that binds to human serum albumin comprising:
 CDR1 comprising the amino acid sequence `GFTFSSFGMS` (SEQ ID NO: 60) or `SFGMS` (amino acids 1-5 of SEQ ID NO: 60);
 CDR2 comprising the amino acid sequence `SISGSGSDTLYADSVKG` (SEQ ID NO: 61) or
 10 `SISGSGSDTL` (amino acids 1-10 of SEQ ID NO: 61); and
 CDR3 comprising the amino acid sequence `GGSLSR` (SEQ ID NO: 62).
13. The multispecific binder of claim 12 wherein the human serum albumin ISVD comprises the amino acid sequence:
 15 `EVQLVESGGG VVQPGNSLR L SCAASGFTFS SFGMSWVRQA PGKGLEWVSS ISGSGSDTLYADSVKGRFTI`
`SRDNAKTTLY LQMNSLRPED TALYYCTIGG SLRSRSGQTL VTVSSA`
 (SEQ ID NO: 59)
14. A binder that cross-blocks a binder of any one of claims 1-13 from binding to LAG3 or
 20 PD1 and LAG3.
15. An injection device or vessel that comprises the binder of any one of claims 1-14, optionally in association with a further therapeutic agent.
- 25 16. A polynucleotide encoding the binder of any one of claims 1-14.
17. A vector comprising the polynucleotide of claim 16.
18. A host cell comprising the polynucleotide or vector of any one of claims 16-17.
 30
19. A method for making a binder of any one of claims 1-14 comprising introducing a polynucleotide encoding the binder into a host cell and culturing the host cell in a medium under

conditions favorable to expression of said binder from said polynucleotide and, optionally, purifying the binder from said host cell and/or said medium.

20. A binder produced by the method of claim 19.

5

21. A method for preventing PD1 from binding to PD-L1 and/or PD-L2 comprising contacting the PD1 with said binder of any one of claims 1, 2, 3 or 6-14 optionally in association with a further therapeutic agent.

10 22. A method for preventing LAG3 from binding to MHC class II comprising contacting said LAG3 with a binder of any one of claims 4-14, optionally in association with a further therapeutic agent.

15 23. A method for enhancing an immune response in a subject comprising administering an effective amount of binder of any one of claims 1-14 to the subject, optionally in association with a further therapeutic agent.

20 24. A method for treating or preventing cancer or an infectious disease in a human subject comprising administering an effective amount of binder of any one of claims 1-14, optionally in association with a further therapeutic agent, to the subject.

25 25. The method claim 24 wherein the cancer is metastatic cancer, a solid tumor, a hematologic cancer, leukemia, lymphoma, osteosarcoma, rhabdomyosarcoma, neuroblastoma, kidney cancer, leukemia, renal transitional cell cancer, bladder cancer, Wilm's cancer, ovarian cancer, pancreatic cancer, breast cancer, prostate cancer, bone cancer, lung cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, cervical cancer, synovial sarcoma, head and neck cancer, squamous cell carcinoma, multiple myeloma, renal cell cancer, retinoblastoma, hepatoblastoma, hepatocellular carcinoma, melanoma, rhabdoid tumor of the kidney, Ewing's sarcoma, chondrosarcoma, brain cancer, glioblastoma, meningioma, pituitary adenoma, vestibular schwannoma, a primitive neuroectodermal tumor, medulloblastoma, astrocytoma, anaplastic astrocytoma, oligodendroglioma, ependymoma, choroid plexus papilloma, polycythemia vera,

30

thrombocythemia, idiopathic myelofibrosis, soft tissue sarcoma, thyroid cancer, endometrial cancer, carcinoid cancer or liver cancer, breast cancer or gastric cancer.

26. The method claim 24 wherein the infectious disease is a bacterial infection, a viral
5 infection or a fungal infection.

27. The method of any one of claims 24-26 wherein the subject is administered a further therapeutic agent or a therapeutic procedure in association with the binder.